Idexx Laboratories

IDXX

Market cap $56.2B

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX's Board of Directors (the “Board”). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Comp.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2025 Earnings Snapshot through a link on.

CNBC's “Halftime Report” Investment Committee discuss their top stocks to watch for the second half of the day's trading session.

IDXX shares surge 64.7% in a year as CAG Diagnostics momentum, strong retention and expanding software adoption fuel growth across regions.

NVIDIA, IDXX and Microsoft shine on ESG metrics, fueling investor interest with strong returns and ambitious 2030 goals.

Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.

VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.

Boosted by solid growth and clear demand among the best mutual funds, Idexx stock has blasted out into buy range.

ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.

IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.